Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119794 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
A Phase 2 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01119794 is a Phase 2 study that was terminated before completion, run by Brown University. The registered enrollment target is 10 participants.
The verdict
NCT01119794, a Phase 2 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma (LG-NHL) that relapse beyond 6 months of a previous rituximab-containing regimen.
Interventions
- DRUG Ofatumumab and Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119794
The ClinicalTrials.gov registry entry for NCT01119794 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ofatumumab and Bortezomib is the first listed.
NCT01119794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119794 about?
NCT01119794 is a clinical study titled "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab". The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma (LG-NHL) that relapse beyond 6 months of a previous rituximab-containing regimen.
What is the current status of trial NCT01119794?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01119794?
The interventions under investigation include: Ofatumumab and Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01119794?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.